
Please try another search
By Davit Kirakosyan
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shares were trading more than 3% lower after-hours following the company’s announcement, according to which the U.S. Food and Drug Administration (FDA) placed a clinical hold on SRP-5051 (vesleteplirsen) for the treatment of Duchenne muscular dystrophy.
The hold is placed on 5051-201, the Phase 2, multi-arm, ascending dose study of SRP-5051, also known as MOMENTUM, following a serious adverse event of hypomagnesemia.
The company said it will respond to the FDA in the next few days with the requested information on all cases of hypomagnesemia, including a small number of non-serious grade 2 cases, to assess the adequacy of the risk mitigation and safety monitoring plan.
By Zhang Mengying Investing.com – Asia Pacific stocks were mixed on Thursday morning as investors assessed comments from central bank chiefs on tackling red hot inflation...
By Oliver Gray Investing.com - U.S. stock index futures were flat during overnight trading Wednesday, following a mixed session among major benchmark averages as investors remain...
By Davit Kirakosyan Xerox (NASDAQ:XRX) made an announcement, according to which John Visentin, Vice Chairman and CEO, who joined the company in 2018, passed away unexpectedly...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.